Over the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with ...

Pastor Kelvis Reid knew that he was taking a risk wrapping Christmas presents with his family, but he couldn't imagine spending the holidays any other way. He had just been diagnosed with a ...

Pastor Kelvis Reid knew that he was taking a risk wrapping Christmas presents with his family, but he couldn't imagine spending the holidays any other way. He had just been diagnosed with a ...

Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage. Two main forms exist: hereditary ATTR (ATTRv), linked to ...

A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors. By Simar Bajaj When James Hicks, 75, was diagnosed with heart failure, it ...

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Anselamimab did not meet main goal in overall study population Therapy shows improvement in pre-specified patient subgroup AstraZeneca plans to share data with regulators July 16 (Reuters) - ...

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial. The British-Swedish pharmaceutical company said Wednesday that the phase III of its ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. The Big ...

Compared with placebo, significant improvement in survival and cardiovascular hospitalization was not observed with anselamimab in the overall patient population. Topline data were announced from a ...

Absence of neurotoxicity of any grade in low-volume disease to-date highlights a significant safety profile for NXC-201, which is crucial for patient acceptance and regulatory approval. Company is on ...

Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...